Abstract

This new application seeks to test the involvement of the p53 protein in the evolution of prostate cancer to an androgen-independent state.
Aim 1 is to determine the growth response to androgens of androgen-sensitive human prostate cell lines in vivo and in vitro.
Aim 2 is to study the impact of inactivation of the p53 protein on growth responses to androgens in androgen-sensitive human prostate cancer cell lines.
Aim 3 is to determine the effects of expressing a wild type p53 gene in androgen-insensitive prostate cancer cell lines lacking endogenous p53 protein.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29CA075499-02
Application #
2733391
Study Section
Biochemical Endocrinology Study Section (BCE)
Program Officer
Mohla, Suresh
Project Start
1997-07-01
Project End
2002-06-30
Budget Start
1998-07-01
Budget End
1999-06-30
Support Year
2
Fiscal Year
1998
Total Cost
Indirect Cost

  Institution

Name
University of Texas MD Anderson Cancer Center
Department
Dentistry
Type
Other Domestic Higher Education
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030

  Publications

Fizazi, Karim; Sikes, Charles R; Kim, Jeri et al. (2004) High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer. Anticancer Res 24:2897-903
Fizazi, Karim; Yang, Jun; Peleg, Sara et al. (2003) Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res 9:2587-97
Fizazi, Karim; Martinez, Luis A; Sikes, Charles R et al. (2002) The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer. Clin Cancer Res 8:775-81
Martinez, Luis A; Yang, Jun; Vazquez, Elba S et al. (2002) p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. Carcinogenesis 23:1289-96
Newman, R A; Yang, J; Raymond, M et al. (2001) Antitumor efficacy of 26-fluoroepothilone B against human prostate cancer xenografts. Cancer Chemother Pharmacol 48:319-26
Yang, J; Fizazi, K; Peleg, S et al. (2001) Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res 61:5652-9
Navone, N M; Rodriquez-Vargas, M C; Benedict, W F et al. (2000) TabBO: a model reflecting common molecular features of androgen-independent prostate cancer. Clin Cancer Res 6:1190-7